查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1955081

全球出血性疾病檢測市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析、未來預測（2026-2034）

Bleeding Disorder Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 請詢問到貨日

價格

出血性疾病檢測市場成長驅動因素

2025年全球出血性疾病檢測市場規模為1.098億美元，2026年成長至1.1839億美元，預計到2034年將達到2.2338億美元。 2026年至2034年的複合年增長率（CAGR）為8.26%。歐洲在全球市場中佔領先地位，預計到2025年將佔40.25%的市場佔有率，這得益於其強大的診斷基礎設施和較高的疾病認知度。

出血性疾病是指遺傳性或後天性疾病，會損害人體正常的血液凝固能力，導致持續性或過度出血。 常見疾病包括A型血友病、B型血友病、血管性血友病（VWD）及特發性血小板減少性紫斑症（ITP）。這些疾病盛行率的不斷上升以及診斷平台技術的進步正在推動市場擴張。 市場概覽 出血性疾病檢測市場的成長主要得益於全球診斷率的提高和醫療服務可近性的改善。根據世界血友病聯盟（WFH）統計，2015年至2020年間，出血性疾病的診斷病例數量顯著增加，這凸顯了人們對該疾病的認識不斷提高以及篩檢工作的加強。 凝血分析儀自動化、人工智慧 (AI)、機器學習 (ML) 和奈米診斷技術等技術進步正在改變檢測流程。例如，羅氏宣布擴展其 cobaspro 整合解決方案的配置，以提高處理能力和效率，從而應對日益增長的診斷需求。

新冠疫情的影響

2020 年，由於就診量下降和常規診斷測試的推遲，新冠疫情對市場造成了負面影響。由於醫療系統優先進行新冠病毒檢測，血友病、血管性血友病及相關疾病的檢測數量有所下降。

主要公司的收入出現了暫時性下滑。然而，隨著常規醫療服務的恢復，市場在 2021 年和 2022 年開始復甦。隨著診斷率的提高和新產品的獲批，預計從2025年起市場將持續穩定成長。

市場趨勢

人工智慧在診斷的應用

將人工智慧和機器學習（ML）應用於凝血檢測是一種新的趨勢。人工智慧正被用於預測血友病嚴重程度、識別基因突變以及提高早期診斷的準確性。此外，旨在提高凝血異常檢測靈敏度的奈米診斷技術的研究也不斷推進。

在預測期內，研發投入的增加以及與數位醫療的融合預計將加速檢測設備和軟體平台的創新。

市場成長驅動因素

盛行率和診斷率的上升

出血性疾病在全球盛行率的上升是推動市場成長的主要因素。血友病A仍是最常見的嚴重遺傳性出血性疾病，在全球確診病例中佔相當大的比例。美國國家血友病基金會和世界血友病聯盟等組織發布的最新臨床指南和進行的宣傳活動正在促進早期診斷。

新興國家醫療基礎設施的改善也促進了檢測量的增加。

研發投入增加及產品上市

持續的產品創新正在推動市場成長。各公司正在開發先進的止血分析儀和試劑盒，以提高實驗室效率和自動化程度。政府支持的針對罕見血液疾病的措施和慈善資助計畫正在進一步加速診斷技術的進步。

市場限制因子

儘管成長前景強勁，但市場仍面臨諸多挑戰，例如新興市場檢測普及率低、診斷指南執行不力以及先進設備和試劑成本高昂。在醫療資源有限的地區，早期診斷仍然困難，這限制了市場擴張。

市場區隔分析

依產品類型

市場依產品類型細分為試劑和耗材以及設備。

  • 試劑和耗材佔最大市場佔有率（截至2026年為69.34%），預計由於檢測頻率的增加和持續的需求，其增長速度也將最快。
  • 在凝血分析儀自動化和技術進步的推動下，設備細分市場預計將穩定成長。

依適應症劃分

此市場依適應症細分為：血友病A、血管性血友病、血友病B、特發性血小板減少性紫斑症 (ITP) 等。

  • 到2026年，由於血友病A的高發生率和篩檢的增加，它將佔46.19%的市場佔有率。
  • 由於血管性血友病在全球範圍內的發生率相對較高，它也佔了相當大的市場佔有率。

依最終使用者劃分

此市場細分為：醫院和診所、診斷中心和其他。

  • 由於病患數量增加和檢測設施的完善，到2026年，醫院和診所將佔60.31%的市場佔有率。
  • 由於自動化分析儀的日益普及，診斷中心預計將擁有最高的複合年增長率。

區域洞察

歐洲

歐洲預計將成為最大的市場，2025 年市場規模為 4,420 萬美元，2026 年為 4,775 萬美元。該地區受益於健全的監管框架、較高的認知度和完善的診斷指南。

北美

在監管審批和產品上市的支持下，北美預計將顯著成長。 2026 年美國市場價值為 2,898 萬美元。

亞太及其他地區 (ROW)

中國、日本和印度等新興市場正在經歷醫療保健基礎設施的擴張和對罕見疾病認知度的提高。預計到 2026 年，中國市場規模將達到 1,742 萬美元，而日本和印度的市場規模預計分別為 385 萬美元和 306 萬美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家出血性疾病盛行率（2025 年）
  • 主要公司新產品上市狀況
  • 全球出血性疾病檢測市場的技術進步
  • 新冠疫情對市場的影響

第五章 全球出血性疾病檢測市場分析：洞察與展望

預測（2021-2034）
  • 市場分析、洞察與預測：依產品類型劃分
    • 試劑和耗材
    • 設備
  • 市場分析、洞察與預測：依適應症劃分
    • 血友病A
    • 血友病B
    • 血管性血友病
    • 特發性血小板減少性紫斑症（ITP）
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 診斷中心
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區全球

第六章 北美出血性疾病檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲出血性疾病檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 其他歐洲地區

第八章 亞太地區出血性疾病檢測市場分析：洞察與預測（2021-2034）

  • 國家細分市場
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他亞太地區

第九章 其他地區（ROW）出血性疾病檢測市場分析：洞察與預測（2021-2034）

第10章 競爭分析

  • 全球市場佔有率分析(2025年)
  • 企業簡介
    • Siemens Healthcare GmbH
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Atlas Medical GmbH
    • HORIBA, Ltd.
    • Sysmex Corporation
    • HYPHEN BioMed
    • Precision BioLogic Incorporated
    • Other Players
Product Code: FBI106908

Growth Factors of bleeding disorders testing Market

The global bleeding disorders testing market was valued at USD 109.8 million in 2025 and is projected to grow to USD 118.39 million in 2026, reaching USD 223.38 million by 2034, exhibiting a CAGR of 8.26% during 2026-2034. Europe dominated the global market with a 40.25% share in 2025, supported by strong diagnostic infrastructure and high disease awareness.

Bleeding disorders are inherited or acquired conditions that impair the body's ability to clot blood properly, resulting in prolonged or excessive bleeding. Common conditions include Hemophilia A, Hemophilia B, Von Willebrand Disease (VWD), and idiopathic thrombocytopenic purpura (ITP). The increasing prevalence of these disorders, along with technological advancements in diagnostic platforms, is driving market expansion.

Market Overview

The growth of the bleeding disorders testing market is primarily fueled by rising diagnosis rates and improved access to healthcare services globally. According to the World Federation of Hemophilia, the number of diagnosed bleeding disorder cases increased significantly between 2015 and 2020, highlighting growing awareness and screening efforts.

Technological advancements, including automation in coagulation analyzers, artificial intelligence (AI), machine learning (ML), and nano-diagnostics, are transforming testing procedures. For example, Roche launched expanded configurations for its Cobas pro integrated solutions to improve throughput and efficiency, supporting increased diagnostic demand.

COVID-19 Impact

The COVID-19 pandemic negatively affected the market in 2020 due to reduced hospital visits and postponement of routine diagnostic procedures. Testing for hemophilia, Von Willebrand disease, and related conditions declined as healthcare systems prioritized COVID-19 testing.

Major companies experienced temporary revenue declines. However, recovery began in 2021 and 2022 as routine healthcare services resumed. Increased diagnosis rates and new product approvals are expected to sustain steady growth from 2025 onward.

Market Trends

Integration of Artificial Intelligence in Diagnostics

The implementation of AI and ML in coagulation testing is an emerging trend. AI is being explored for predicting hemophilia severity, identifying gene mutations, and enhancing early diagnosis accuracy. Additionally, nano-diagnostic technologies are being studied for improved sensitivity in detecting clotting abnormalities.

Growing R&D investments and digital health integration are expected to accelerate innovation in testing instruments and software platforms during the forecast period.

Market Growth Drivers

Rising Prevalence and Diagnosis Rates

The increasing global prevalence of bleeding disorders is a key growth driver. Hemophilia A remains the most common severe inherited bleeding disorder, accounting for a substantial portion of diagnosed cases worldwide. Updated clinical guidelines and awareness campaigns by organizations such as the National Hemophilia Foundation and the World Federation of Hemophilia are promoting early diagnosis.

Improved healthcare infrastructure in emerging economies is also contributing to higher testing volumes.

Increasing R&D and Product Launches

Continuous product innovation is strengthening market growth. Companies are developing advanced hemostasis analyzers and reagent kits to improve efficiency and automation in laboratories. Government-backed initiatives and philanthropic funding programs aimed at rare blood disorders are further accelerating diagnostic advancements.

Market Restraints

Despite strong growth prospects, the market faces challenges such as low testing penetration in emerging countries, limited adherence to diagnostic guidelines, and high costs of advanced instruments and reagents. In regions with limited healthcare funding, early diagnosis remains a challenge, restricting market expansion.

Segmentation Analysis

By Product Type

The market is segmented into reagents & consumables and instruments.

  • Reagents & consumables held the largest share (69.34% in 2026) and are expected to grow at the fastest rate due to increasing testing frequency and recurring demand.
  • The instruments segment is projected to grow steadily, supported by automation and technological advancements in coagulation analyzers.

By Indication

The market is segmented into Hemophilia A, Von Willebrand Disease, Hemophilia B, ITP, and others.

  • Hemophilia A dominated the market in 2026 with a 46.19% share, driven by high disease prevalence and increased screening.
  • Von Willebrand disease represents a significant segment due to its relatively higher occurrence globally.

By End-user

The market is categorized into hospitals & clinics, diagnostic centers, and others.

  • Hospitals & clinics accounted for 60.31% of the market in 2026, owing to higher patient inflow and established laboratory facilities.
  • Diagnostic centers are expected to witness the highest CAGR due to rising adoption of automated analyzers.

Regional Insights

Europe

Europe led the market with a valuation of USD 44.2 million in 2025 and USD 47.75 million in 2026. The region benefits from strong regulatory frameworks, high awareness levels, and established diagnostic guidelines.

North America

North America is projected to witness significant growth, supported by regulatory approvals and product launches. The U.S. market is valued at USD 28.98 million in 2026.

Asia Pacific and Rest of the World

Emerging economies such as China, Japan, and India are expanding healthcare infrastructure and increasing rare disease awareness. China's market is valued at USD 17.42 million in 2026, while Japan and India are valued at USD 3.85 million and USD 3.06 million in 2026, respectively.

Competitive Landscape

The market is fragmented with key players including F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Sysmex Corporation, HORIBA Ltd., Abbott, Thermo Fisher Scientific Inc., Atlas Medical GmbH, HYPHEN BioMed, and Precision Biologics.

Companies are focusing on product approvals, strategic collaborations, mergers & acquisitions, and expansion of diagnostic portfolios to strengthen their competitive position.

Conclusion

The global bleeding disorders testing market is poised for steady expansion, growing from USD 109.8 million in 2025 to USD 223.38 million by 2034, at a CAGR of 8.26%. Growth is driven by increasing disease prevalence, rising diagnosis rates, technological advancements in coagulation testing, and expanding healthcare infrastructure. Europe currently leads the market, while North America and Asia Pacific are expected to witness substantial growth. Despite challenges such as limited testing penetration in emerging regions, ongoing innovation and awareness initiatives will continue to support long-term market growth through 2034.

Segmentation By Product Type

  • Reagents & Consumables
  • Instruments

By Indication

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Idiopathic Thrombocytopenic Purpura
  • Others

By End-user

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Bleeding Disorders, by Key Countries, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Technological Advancements in the Global Bleeding Disorders Testing Market
  • 4.4. Impact of COVID-19 on the Market

5. Global Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Reagents & Consumables
    • 5.1.2. Instruments
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Hemophilia A
    • 5.2.2. Hemophilia B
    • 5.2.3. Von Willebrand Disease
    • 5.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Diagnostic Centers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Reagents & Consumables
    • 6.1.2. Instruments
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Hemophilia A
    • 6.2.2. Hemophilia B
    • 6.2.3. Von Willebrand Disease
    • 6.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Diagnostic Centers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Reagents & Consumables
    • 7.1.2. Instruments
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Hemophilia A
    • 7.2.2. Hemophilia B
    • 7.2.3. Von Willebrand Disease
    • 7.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Diagnostic Centers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Reagents & Consumables
    • 8.1.2. Instruments
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Hemophilia A
    • 8.2.2. Hemophilia B
    • 8.2.3. Von Willebrand Disease
    • 8.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Reagents & Consumables
    • 9.1.2. Instruments
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Hemophilia A
    • 9.2.2. Hemophilia B
    • 9.2.3. Von Willebrand Disease
    • 9.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Diagnostic Centers
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Siemens Healthcare GmbH
      • 10.2.1.1. Overview
      • 10.2.1.2. Product
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. financials (Based on Availability)
    • 10.2.2. F. Hoffmann-La Roche Ltd.
      • 10.2.2.1. Overview
      • 10.2.2.2. Product
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. financials (Based on Availability)
    • 10.2.3. Thermo Fisher Scientific Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Product
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. financials (Based on Availability)
    • 10.2.4. Abbott Laboratories
      • 10.2.4.1. Overview
      • 10.2.4.2. Product
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. financials (Based on Availability)
    • 10.2.5. Atlas Medical GmbH
      • 10.2.5.1. Overview
      • 10.2.5.2. Product
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. financials (Based on Availability)
    • 10.2.6. HORIBA, Ltd.
      • 10.2.6.1. Overview
      • 10.2.6.2. Product
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. financials (Based on Availability)
    • 10.2.7. Sysmex Corporation
      • 10.2.7.1. Overview
      • 10.2.7.2. Product
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. financials (Based on Availability)
    • 10.2.8. HYPHEN BioMed
      • 10.2.8.1. Overview
      • 10.2.8.2. Product
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. financials (Based on Availability)
    • 10.2.9. Precision BioLogic Incorporated
      • 10.2.9.1. Overview
      • 10.2.9.2. Product
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. financials (Based on Availability)
    • 10.2.10. Other Players

List of Tables

  • Table 1: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 2: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 3: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 4: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 6: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 7: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 8: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 10: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 11: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 12: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 14: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 15: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 16: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 18: Rest of the World Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 19: Rest of the World Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034

List of Figures

  • Figure 1: Global Bleeding Disorders Testing Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Bleeding Disorders Testing Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global Bleeding Disorders Testing Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Bleeding Disorders Testing Market Value (USD million), by Region, 2025 & 2034
  • Figure 6: North America Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 7: North America Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 8: North America Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 9: North America Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 10: North America Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 11: North America Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 12: North America Bleeding Disorders Testing Market Value (USD million), By Country, 2025 & 2034
  • Figure 13: North America Bleeding Disorders Testing Market Value Share (%), By Country, 2025
  • Figure 14: Europe Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 15: Europe Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 16: Europe Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 17: Europe Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 18: Europe Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 19: Europe Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Bleeding Disorders Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Bleeding Disorders Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 23: Asia Pacific Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 24: Asia Pacific Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Bleeding Disorders Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Bleeding Disorders Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 31: Rest of the World Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 32: Rest of the World Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 33: Rest of the World Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 34: Rest of the World Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 35: Rest of the World Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 36: Global Bleeding Disorders Testing Market Share (%), By Company, 2025